Healthcare Cost Development in a Type 2 Diabetes Patient Population on Glucose-Lowering Drug Treatment: A Nationwide Observational Study 2006–2014

PharmacoEconomics - Open - Switzerland
doi 10.1007/s41669-017-0063-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Impact of Visit-To-Visit Fasting Plasma Glucose Variability on the Development of Type 2 Diabetes: A Nationwide Population-Based Cohort Study

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2018English

Effects of Intensive Glucose Lowering in Type 2 Diabetes

Yearbook of Endocrinology
2009English

Seasonal Variation in Severe Glucose-Lowering Drug-Induced Hypoglycemia in Patients With Type 2 Diabetes

Internal Medicine
Internal MedicineMedicine
2019English

Blood Glucose-Lowering Therapy in Adults With Type 2 Diabetes

Nurse Prescribing
2016English

Bromocriptine as a Potential Glucose-Lowering Agent for the Treatment of Prolactinoma With Type 2 Diabetes

Internal Medicine
Internal MedicineMedicine
2019English

Impact of Cancer on Adherence to Glucose-Lowering Drug Treatment in Individuals With Diabetes

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Fournier’s Gangrene in a Patient on Dapagliflozin Treatment for Type 2 Diabetes

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

Trend of Cost of Newer Glucose-Lowering Agents in Patients With Type 2 Diabetes Mellitus: Evidence From a Medical System in Taiwan

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Impact of Cancer on Use of Glucose-Lowering Drug Treatment in Individuals With Diabetes: Potential Mechanisms

Diabetologia
Internal MedicineEndocrinologyMetabolismDiabetes
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy